Jennifer Rosenthal
Corporate Officer/Principal at VIRALYTICS LTD.
Profile
Jennifer Rosenthal is currently the Director of Quality & Regulatory Affairs at Viralytics Pty Ltd.
and the Director of Quality & Regulatory Affairs at Clarity Pharmaceuticals Ltd.
She previously worked as the Director of Clinical & Regulatory Affairs at The Sustainable Nutrition Group Pty Ltd.
Dr. Rosenthal holds a doctorate degree from Monash University.
Jennifer Rosenthal active positions
| Companies | Position | Start |
|---|---|---|
| VIRALYTICS LTD. | Corporate Officer/Principal | - |
| CLARITY PHARMACEUTICALS LTD | General Counsel | 2019-09-30 |
Former positions of Jennifer Rosenthal
| Companies | Position | End |
|---|---|---|
| THE SUSTAINABLE NUTRITION GROUP LTD | Chief Tech/Sci/R&D Officer | - |
Training of Jennifer Rosenthal
| Monash University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CLARITY PHARMACEUTICALS LTD | Health Technology |
| Private companies | 2 |
|---|---|
The Sustainable Nutrition Group Pty Ltd.
 The Sustainable Nutrition Group Pty Ltd. Agricultural Commodities/MillingProcess Industries The Sustainable Nutrition Group Ltd. produces, manufactures, and distributes a range of hemp products in Australia. It is involved in hemp seed selection, farming, processing, and packaging, as well as distribution and sale of bulk and retail products. The company's products include hand sanitizers, hemp oils, hemp seeds, hemp protein powders, and hemp flour under the APH and Mt Elephant brands to retail, wholesale, and white label customers. The company was founded by James Hood and Tracie Rams dale in 1995 and is headquartered in Newtown, Australia. | Process Industries |
Viralytics Pty Ltd.
 Viralytics Pty Ltd. BiotechnologyHealth Technology Viralytics Pty Ltd. engages in the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to infect and kill cancer cells. Its product, CAVATAK, is a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21. The company was founded in 1984 and is headquartered in Sydney, Australia. | Health Technology |
- Stock Market
- Insiders
- Jennifer Rosenthal
